Based on the documented need for additional education in prostate cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in Prostate Cancer.
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
Lantheus Medical Imaging
Novartis Pharmaceuticals Corporation
Biomarkers and Molecular Imaging for Prostate Cancer
AUAUniversity · Biomarkers and Molecular Imaging for Prostate Cancer
- Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.
- Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.
- Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.
CME Available: https://auau.auanet.org/node/41727
Appropriate Use of Genetic Testing (who, what, when and how?)
AUAUniversity · Appropriate Use of Genetic Testing (who, what, when and how?)
- Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.
- Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.
- Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.
CME Available: https://auau.auanet.org/node/41734
Treatment Intensification in Metastatic HSPC
AUAUniversity · Treatment Intensification in Metastatic HSPC
- Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology.
- Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks.
- Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.
CME Available: https://auau.auanet.org/node/41733
Sequencing Of Agents
AUAUniversity · Sequencing Of Agents
- Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.
- Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.
- Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.
CME Available: https://auau.auanet.org/node/41735